[Featured Stock] Hwail Pharm Gains on News of Absorption Merger with Kumho HT and Dinona

[Asia Economy Reporter Yoo Hyun-seok] Hwail Pharmaceutical is showing strong performance.

As of 10:41 AM on the 27th, Hwail Pharmaceutical was trading at 12,750 KRW, up 8.51% (1,000 KRW) compared to the previous trading day.

The news of Kumho HT's merger by absorption with Dinona is interpreted as the reason for the strong performance of Hwail Pharmaceutical, an affiliate company.

On this day, Kumho HT announced that it had decided to merge by absorption with Dinona, a developer of immune-oncology antibody therapeutics. The merger ratio between Kumho HT and Dinona is 1 to 1.7390213, and the merger date is July 12.

According to the announcement on the 26th, Hwail Pharmaceutical's largest shareholders have changed to Dinona and two others (Oseong Advanced Materials, S-Mac), holding 24.05% (5,260,266 shares).